Pharmaceutical Sciences and Innovations in Pharma Industry

June 24-25, 2022 | Germany

Pharmaceutical Sciences
Conferenceseries LLC Ltd is an amalgamation of Open Access Publications and worldwide international science conferences and events.

Spotlight

The FDA’s cGMPs for the 21st Century: A Risk-Based Approach Initiative In early 2002, the Food and Drug Administration (FDA) announced their Pharmaceutical cGMPs for the 21st Century: A Risk-Based Approach initiative. According to the FDA position paper: “The FDA oversees the quality of drug products using a two-pronged approach involving review of information submitted in applications as well as inspection of manufacturing facilities for conformance to requirements for current Good Manufacturing Practice (cGMP). These two programs have served the country well by helping to ensure the quality of drug products available in the US. Now, as we approach the 25th anniversary of the last major revision to the drug cGMP regulations, it is time to step back and evaluate the currency of these programs.


OTHER PAST CONFERENCES

World Drug Safety Congress Europe

September 27-29, 2022 | USA

The World Drug Safety Congress Europe is empowering patients, physicians, pharma, biotech and consumers to make the best drug safety decisions.

3rd International Pharmaceutical Conference and Expo

September 29-30, 2022 | UK

3rd International Pharmaceutical Conference and Expo welcome you as our guest to London, UK on September 29-30, 2022. i-Pharma 2022 includes nearly every permutation of knowledge, innovation, technology, and networking; and has the objective of creating an international forum for academicians,

WORLD DRUG SAFETY CONGRESS AMERICAS 2022

October 4-5, 2022 | USA

American Congress on Pharmacovigilance. The annual World Drug Safety Congress Americas addresses the key challenges for drug safety & pharmacovigilance professionals Worldwide

DigIT Pharma Commercial Excellence & Digital Health

September 28-29, 2022 | Germany

Future of Pharma Business: New Pharma Business Unit Opportunities – Datengetriebene Business Itelligence und Commercial Excellence in Zeiten von DIGAs,

Spotlight

The FDA’s cGMPs for the 21st Century: A Risk-Based Approach Initiative In early 2002, the Food and Drug Administration (FDA) announced their Pharmaceutical cGMPs for the 21st Century: A Risk-Based Approach initiative. According to the FDA position paper: “The FDA oversees the quality of drug products using a two-pronged approach involving review of information submitted in applications as well as inspection of manufacturing facilities for conformance to requirements for current Good Manufacturing Practice (cGMP). These two programs have served the country well by helping to ensure the quality of drug products available in the US. Now, as we approach the 25th anniversary of the last major revision to the drug cGMP regulations, it is time to step back and evaluate the currency of these programs.

resources